A study from Yoshito's group demonstrated that a novel drug, C‐122, inhibits tumour growth in hepatocellular carcinoma through down‐regulation of TCF4 and downstream genes such as SPP1, AXIN2, MMP7, ASPH, CD24, ANXA1 and CAMK2N1.56 The gene discussed is ANXA1; the disease is neoplasm.